VYNE Therapeutics Shares Plummet As Mid-Stage Skin Disease Study Missed Primary Endpoint

VYNE Therapeutics Inc. VYNE announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).

The Phase 2a study was designed to evaluate four weeks of FMX114 treatment in 25 enrolled patients with mild-to-moderate AD compared to vehicle control.

The enrollment standard indicated that patients must have two comparable target AD lesions for treatment upon entry.

The study VY2021-01 did not meet its primary endpoint based on the absolute and percent change relative to baseline in the Atopic Dermatitis Severity Index.

David Domzalski, Chief Executive Officer, commented: ”We’re obviously very disappointed by the outcome of this trial for FMX114. We will continue to thoroughly review the full data set and complete our analysis. In addition, as a result of this outcome, our management team and our board of directors will evaluate the Company's pipeline and prioritization of activities."

Price Action : VYNE shares are trading around 34 percent down at $0.27 on Wednesday at the time of publication.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksHealth CareMovers & ShakersMarketsGeneralClinical Study Results
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!